U.S. Markets open in 3 hrs 22 mins

Alexion to Acquire Wilson Therapeutics for $855 Million

Sarah Collins
Alexion to Acquire Wilson Therapeutics for $855 Million

On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.